# Pamishield signs KRW 1.3B supply deal with UCB Pharma

Pamishield has signed a contract with UCB PHARMA S.A. to supply the pharmaceutical intermediate mPEG. The contract is valued at KRW 1,325,300,000 and runs until June 29, 2020.

- Type: Contract
- Announced: 2020-01-10
- Where: South Korea
- Value: $1.13M (1.33B KRW)
- Status: completed
- Products: mPEG pharmaceutical intermediate
- Sectors: [Specialty Chemicals](https://endata.com/sectors/specialty-chemicals.md)

## Companies

- [Pamishield](https://endata.com/companies/21618.md) (supplier)
- [UCB PHARMA S.A.](https://endata.com/companies/44429.md) (customer)

## Sources

- [biz.heraldcorp.com](https://biz.heraldcorp.com/article/2200820), 2020-01-10: "파미셀은 UCB PHARMA S.A.와 의약중간체 mPEG 공급계약을 체결했다고 10일 공시했다."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.